Rob Lewis

Many of us who have spent our careers in the life sciences are keen to accelerate the time it takes to get much-needed therapies to market. We don’t want to keep patients waiting. There are many ways to tackle the problem of selecting and de-risking therapeutic assets. At Roxi-AI, we have seen the inefficiency in this process as we’ve worked side by side with biopharma, clinical development service providers, and investors, de-risking assets and optimizing their profiles to increase commercial success. Every organization has its process, criteria, and a team of individuals to drive asset prioritization decisions. Sometimes, they get it right, but all too often, they don’t. The consequences are lost time and money and patient frustration. It’s time to take the guesswork out of deciding which assets to keep, which ones to kill, and which to remediate to get on the right path.